Treatment and diagnosis of melanoma
The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
1. A method of treating metastatic melanoma in a subject in need thereof, said method comprising administering to the subject an LXRβ agonist selected from:
or a pharmaceutically acceptable salt thereof in an amount sufficient to suppress metastatic progression of said melanoma.
2. The method of claim 1 , wherein said metastatic melanoma is resistant to vemurafenib and/or dacarbazine.
3. The method of claim 1 , wherein said LXRβ agonist is compound 1, or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein said LXRβ agonist is compound 2, or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein said LXRβ agonist is compound 12, or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein said LXRβ agonist is compound 25, or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein said metastatic melanoma is resistant to dacarbazine, a BRAF inhibitor, a MEK inhibitor, a CTLA-4 inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor.
8. The method of claim 1 , wherein the method does not comprise further concurrently administering to the subject an antiproliferative agent.
9. The method of claim 1 , wherein said method further comprises administration of an additional anticancer therapy.
10. The method of claim 9 , wherein said additional anticancer therapy is an antiproliferative.
11. The method of claim 10 , wherein said antiproliferative is a PD1 inhibitor, a VEGF inhibitor, a VEGFR2 inhibitor, a CTLA4 inhibitor, and/or a PDL1 inhibitor.
12. The method of claim 10 , wherein said antiproliferative is a PD-1 inhibitor or a PD-L1 inhibitor.
13. The method of claim 10 , wherein said antiproliferative is nivolumab, ipilmumab, dacarbazine, or vemurafenib.
14. The method of claim 1 , wherein said method comprises suppressing metastatic colonization of the melanoma to the lung and/or the brain.